{"id":4973,"date":"2025-07-02T08:26:56","date_gmt":"2025-07-02T06:26:56","guid":{"rendered":"https:\/\/cvja.co.za\/journal\/?p=4973"},"modified":"2025-07-08T10:29:39","modified_gmt":"2025-07-08T08:29:39","slug":"cvja-2025-015","status":"publish","type":"post","link":"https:\/\/cvja.co.za\/journal\/cvja-2025-015\/","title":{"rendered":"Effects of edoxaban, rivaroxaban, and warfarin on recanalisation, inflammation, and post-thrombotic syndrome in patients with deep vein thrombosis"},"content":{"rendered":"    <div id=\"article\">                                                                                                                        \r\n        <div id=\"title-container\">                                                                                                    \r\n        <div id=\"authors-title\">                                                                                                            \r\n        <!--Aurthors under Title-->                                                                                                            \r\n            Volkan Burak Taban, Abdullah G\u00fcner, \u00d6zg\u00fcr Alt\u0131nbas, Y\u00fcksel Dereli                                                                                                        \r\n        <\/div>        \r\n<\/div>                                                                                                                            \r\n            <div id=\"copyright\">\r\n        <strong>Copyright:<\/strong> Clinics Cardive Publishing (Pty) Ltd. publisher\r\n        of Cardiovascular Journal of Africa.<\/div>\r\n    <div style=\"clear: both;\"><\/div>                                                                                                                                \r\n        <div id=\"article-abstract\">                                                                                                            \r\n            <div id=\"abstract-title\">                                                                                                        \r\n                    Abstract                                                                                                                \r\n                <\/div>                                                                                                                        \r\n                                                                                                                                \r\n            <div id=\"abstract-content\">                                                                                                        \r\n            <!--Content of Abstract Article-->                                                                                                \r\n            <!--<strong>\"Abstract titles\":<\/strong>-->                                                                                        \r\n            <!--<br\/> at the end of each section!!-->                                                                                        \r\n                                                                                                                                            \r\n        <strong>Objective:<\/strong>                                                                                                    \r\n                                                                                                                                                    \r\n        Post-thrombotic syndrome (PTS) and recurrent thrombosis are the common morbidities associated with deep venous thrombosis (DVT). There are several treatment modalities have been defined in the literature. Here, we aimed to compare the effects of edoxaban, rivaroxaban and warfarin on recanalised flow, inflammation and postthrombotic syndrome in patients with DVT.                                                                                                                   \r\n                <br \/>                                                                                                                            \r\n                                                                                                                                                \r\n        <strong>Methods:<\/strong>                                                                                                    \r\n                                                                                                                                                    \r\n        Total of 320 patients treated with Edoxaban 60 mg(n=107), Rivaroxaban 20 mg(n=107) and Warfarin 5 mg(n=106) due to DVT were included to the study. Venous Doppler ultrasonography and VILLALTAscore were used for the assessment of recanalised flow and PTS.                                                                                                                    \r\n                <br \/>                                                                                                                            \r\n                                                                                                                                                \r\n        <strong>Results:<\/strong>                                                                                                    \r\n                                                                                                                                                    \r\n        There were no statistically significant differences between the groups in terms of demographic characteristics. 1-month NLR levels were significantly lower in rivaroxaban group and PLR levels were significantly lower in both rivaroxaban and edoxaban groups. 3-month villalta score was statistically higher inWarfarin group and no differences in 6th month measurements between the groups.                                                                                                                    \r\n                <br \/>                                                                                                                            \r\n                                                                                                                                                \r\n        <strong>Conclusion:<\/strong>                                                                                                    \r\n                                                                                                                                                    \r\n         Treatment of DVT is a dynamic process which requires the exact evaluation of the patients according to the several parameters. Recanalised flow, inflammation and situations related to inflammation such as PTS can be used for the assessment. Drugs can be shifted according to the response.                                                                                                                 \r\n                <br \/>        \r\n\t\t\t\t\r\n\t\t\t\t <strong>Abbreviations and Acronyms:<\/strong>                                                                                                    \r\n                                                                                                                                                    \r\n         DVT: Deep Venous Thrombosis, PTS: Post-thrombotic Syndrome, NOACs: New Oral Anticoagulants, NLR: Neutrophil\/lymphocyte ratio, PLR: Platelet\/lymphocyte ratio, TTR: Time in therapeutic range, QoL: Quality of Life.                                                                                                                 \r\n                <br \/>   \r\n                                                                                                                                                \r\n            <\/div>                                                                                                                            \r\n        <\/div>                                                                                                                                    \r\n                                                                                                                                        \r\n                                                                                                                                                \r\n        <div id=\"keywords\">                                                                                                                    \r\n                                                                                                                                            \r\n            <strong>Keywords:<\/strong>                                                                                                        \r\n                                                                                                                                            \r\n            <strong>venous recanalisation, oral anticoagulation, quality of life, post-thrombotic syndrome<\/strong>                                                                                                                                                                                                                    \r\n                                                                                                                                                \r\n        <\/div>                                                                                                                                    \r\n                                                                                                                                                \r\n    <div id=\"publish-info\">                                                                                                                    \r\n                                                                                                                                \r\n    <strong>Submitted:<\/strong> December 6, 2024; <!--Month day, year; -->    \r\n    <strong>Accepted:<\/strong> February 10, 2025; <!--Month day, year; -->                                                                             \r\n    <strong>Published:<\/strong> June 30, 2025<!--Month day, year; -->                                                                                                                            <br \/>                                                            \r\n        <em>Cardiovasc J Afr 2025; <b>36<\/b>: 154-160<!--pg no. till pg no. \"eg. 4-7\"--><\/em>\r\n        <br \/><strong>Volume 36, Issue 2<\/strong> <br \/>                                                                            \r\n        <\/div>                                                                                                                            \r\n                                                                                                                                        \r\n    <div id=\"DOI\">                                                                                                                    \r\n            DOI Citation Reference: dx.doi.org\/10.5830\/CVJA-2025-015<!--DOI number-->                                                                \r\n        <\/div>                                                                                                                            \r\n                \r\n\t\t\t\t            <div id=\"author-affiliation\">                                                                                                \r\n                                                                                                                                        \r\n                <strong>State Hospital, Department of Cardiovascular Surgery, S\u0131rnak, Turkey<\/strong>    <br \/>                                                                            \r\n                                                                                                                                        \r\n         Volkan Burak Taban, MD<br \/>                                                                                                \r\n                                                                                                                                        \r\n            <\/div>    \r\n                                                                                                                                        \r\n            <div id=\"author-affiliation\">                                                                                                \r\n                                                                                                                                        \r\n                <strong>Beyhekim Training and Research Hospital, Department of Cardiovascular Surgery, Konya, Turkey<\/strong>    <br \/>                                                                            \r\n                                                                                                                                        \r\n           Abdullah G\u00fcner, MD<br \/>                                                                                                \r\n                                                                                                                                        \r\n            <\/div>                                                                                                                        \r\n                                                                                                                                        \r\n            <div id=\"author-affiliation\">                                                                                                \r\n                                                                                                                                        \r\n                <strong>Gaziantep University, Vocational School of Health Services, Department of Operating Room Services, Gaziantep, Turkey<\/strong>    <br \/>                                                                            \r\n                                                                                                                                        \r\n                \u00d6zg\u00fcr Alt\u0131nba\u00b8s, Dr., Assoc.Prof.<br \/>\r\n\t\t\t\t\r\n\t\t\t\t   <div id=\"author-affiliation\">                                                                                                \r\n                                                                                                                                        \r\n                <strong>Necmettin Erbakan University, Meram Medical Faculty, Department of Cardiovascular Surgery, Konya, Turkey<\/strong>    <br \/>                                                                            \r\n                                                                                                                                        \r\n                Y\u00fcksel Dereli, Dr., Prof.<br \/><br \/>\r\n\r\n                [soshsc hide=\"logged\"]\r\n                <strong>You need to be <a style=\"color: #c80c44;\" href=\"https:\/\/cvja.co.za\/journal\/member-login\/\" target=\"_blank\" rel=\"noopener\">logged in to view and download<\/a> the full text PDF version. <a style=\"color: #c80c44;\" href=\"https:\/\/cvja.co.za\/journal\/register\/\" target=\"_blank\" rel=\"noopener\">Register for a free account?<\/a><\/strong> <br \/><br \/>[\/soshsc]\r\n                \r\n                \r\n                \r\n                <\/div>\r\n    \r\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Post-thrombotic syndrome (PTS) and recurrent thrombosis are the common morbidities associated with deep venous thrombosis (DVT). There are several treatment modalities have been defined in the literature. Here, we aimed to compare the effects of edoxaban, rivaroxaban and warfarin on recanalised flow, inflammation and postthrombotic syndrome in patients with DVT.<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[44,101],"tags":[],"class_list":["post-4973","post","type-post","status-publish","format-standard","hentry","category-cardiovascular-topics","category-volume-36-issue-2"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.0 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Effects of edoxaban, rivaroxaban, and warfarin on recanalisation, inflammation, and post-thrombotic syndrome in patients with deep vein thrombosis - Cardiovascular Journal of Africa<\/title>\n<meta name=\"description\" content=\"Treatment of DVT is a dynamic process which requires the exact evaluation of the patients according to the several parameters. Recanalised flow, inflammation and situations related to inflammation such as PTS can be used for the assessment. Drugs can be shifted according to the response.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cvja.co.za\/journal\/cvja-2025-015\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Effects of edoxaban, rivaroxaban, and warfarin on recanalisation, inflammation, and post-thrombotic syndrome in patients with deep vein thrombosis - Cardiovascular Journal of Africa\" \/>\n<meta property=\"og:description\" content=\"Treatment of DVT is a dynamic process which requires the exact evaluation of the patients according to the several parameters. Recanalised flow, inflammation and situations related to inflammation such as PTS can be used for the assessment. Drugs can be shifted according to the response.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cvja.co.za\/journal\/cvja-2025-015\/\" \/>\n<meta property=\"og:site_name\" content=\"Cardiovascular Journal of Africa\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-02T06:26:56+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-08T08:29:39+00:00\" \/>\n<meta name=\"author\" content=\"Jaco Moolman\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Jaco Moolman\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cvja.co.za\/journal\/cvja-2025-015\/\",\"url\":\"https:\/\/cvja.co.za\/journal\/cvja-2025-015\/\",\"name\":\"Effects of edoxaban, rivaroxaban, and warfarin on recanalisation, inflammation, and post-thrombotic syndrome in patients with deep vein thrombosis - Cardiovascular Journal of Africa\",\"isPartOf\":{\"@id\":\"https:\/\/cvja.co.za\/journal\/#website\"},\"datePublished\":\"2025-07-02T06:26:56+00:00\",\"dateModified\":\"2025-07-08T08:29:39+00:00\",\"author\":{\"@id\":\"https:\/\/cvja.co.za\/journal\/#\/schema\/person\/6bf8a30a039e93fd8112db707affb920\"},\"description\":\"Treatment of DVT is a dynamic process which requires the exact evaluation of the patients according to the several parameters. Recanalised flow, inflammation and situations related to inflammation such as PTS can be used for the assessment. Drugs can be shifted according to the response.\",\"breadcrumb\":{\"@id\":\"https:\/\/cvja.co.za\/journal\/cvja-2025-015\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cvja.co.za\/journal\/cvja-2025-015\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cvja.co.za\/journal\/cvja-2025-015\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cvja.co.za\/journal\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Effects of edoxaban, rivaroxaban, and warfarin on recanalisation, inflammation, and post-thrombotic syndrome in patients with deep vein thrombosis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cvja.co.za\/journal\/#website\",\"url\":\"https:\/\/cvja.co.za\/journal\/\",\"name\":\"Cardiovascular Journal of Africa\",\"description\":\"The Cardiovascular Journal of Africa is a peer-reviewed medical journal publishing leading research in cardiovascular health across Africa since 1990\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cvja.co.za\/journal\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/cvja.co.za\/journal\/#\/schema\/person\/6bf8a30a039e93fd8112db707affb920\",\"name\":\"Jaco Moolman\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cvja.co.za\/journal\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/454c6719ed785bfd40e036ca3c3ac3347c56b4a99902df8beb62d882b1e6967f?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/454c6719ed785bfd40e036ca3c3ac3347c56b4a99902df8beb62d882b1e6967f?s=96&d=mm&r=g\",\"caption\":\"Jaco Moolman\"},\"url\":\"https:\/\/cvja.co.za\/journal\/author\/jacodesignconnection-co-za\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Effects of edoxaban, rivaroxaban, and warfarin on recanalisation, inflammation, and post-thrombotic syndrome in patients with deep vein thrombosis - Cardiovascular Journal of Africa","description":"Treatment of DVT is a dynamic process which requires the exact evaluation of the patients according to the several parameters. Recanalised flow, inflammation and situations related to inflammation such as PTS can be used for the assessment. Drugs can be shifted according to the response.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cvja.co.za\/journal\/cvja-2025-015\/","og_locale":"en_US","og_type":"article","og_title":"Effects of edoxaban, rivaroxaban, and warfarin on recanalisation, inflammation, and post-thrombotic syndrome in patients with deep vein thrombosis - Cardiovascular Journal of Africa","og_description":"Treatment of DVT is a dynamic process which requires the exact evaluation of the patients according to the several parameters. Recanalised flow, inflammation and situations related to inflammation such as PTS can be used for the assessment. Drugs can be shifted according to the response.","og_url":"https:\/\/cvja.co.za\/journal\/cvja-2025-015\/","og_site_name":"Cardiovascular Journal of Africa","article_published_time":"2025-07-02T06:26:56+00:00","article_modified_time":"2025-07-08T08:29:39+00:00","author":"Jaco Moolman","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Jaco Moolman","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/cvja.co.za\/journal\/cvja-2025-015\/","url":"https:\/\/cvja.co.za\/journal\/cvja-2025-015\/","name":"Effects of edoxaban, rivaroxaban, and warfarin on recanalisation, inflammation, and post-thrombotic syndrome in patients with deep vein thrombosis - Cardiovascular Journal of Africa","isPartOf":{"@id":"https:\/\/cvja.co.za\/journal\/#website"},"datePublished":"2025-07-02T06:26:56+00:00","dateModified":"2025-07-08T08:29:39+00:00","author":{"@id":"https:\/\/cvja.co.za\/journal\/#\/schema\/person\/6bf8a30a039e93fd8112db707affb920"},"description":"Treatment of DVT is a dynamic process which requires the exact evaluation of the patients according to the several parameters. Recanalised flow, inflammation and situations related to inflammation such as PTS can be used for the assessment. Drugs can be shifted according to the response.","breadcrumb":{"@id":"https:\/\/cvja.co.za\/journal\/cvja-2025-015\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cvja.co.za\/journal\/cvja-2025-015\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/cvja.co.za\/journal\/cvja-2025-015\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cvja.co.za\/journal\/"},{"@type":"ListItem","position":2,"name":"Effects of edoxaban, rivaroxaban, and warfarin on recanalisation, inflammation, and post-thrombotic syndrome in patients with deep vein thrombosis"}]},{"@type":"WebSite","@id":"https:\/\/cvja.co.za\/journal\/#website","url":"https:\/\/cvja.co.za\/journal\/","name":"Cardiovascular Journal of Africa","description":"The Cardiovascular Journal of Africa is a peer-reviewed medical journal publishing leading research in cardiovascular health across Africa since 1990","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cvja.co.za\/journal\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/cvja.co.za\/journal\/#\/schema\/person\/6bf8a30a039e93fd8112db707affb920","name":"Jaco Moolman","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cvja.co.za\/journal\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/454c6719ed785bfd40e036ca3c3ac3347c56b4a99902df8beb62d882b1e6967f?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/454c6719ed785bfd40e036ca3c3ac3347c56b4a99902df8beb62d882b1e6967f?s=96&d=mm&r=g","caption":"Jaco Moolman"},"url":"https:\/\/cvja.co.za\/journal\/author\/jacodesignconnection-co-za\/"}]}},"_links":{"self":[{"href":"https:\/\/cvja.co.za\/journal\/wp-json\/wp\/v2\/posts\/4973","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cvja.co.za\/journal\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cvja.co.za\/journal\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cvja.co.za\/journal\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/cvja.co.za\/journal\/wp-json\/wp\/v2\/comments?post=4973"}],"version-history":[{"count":0,"href":"https:\/\/cvja.co.za\/journal\/wp-json\/wp\/v2\/posts\/4973\/revisions"}],"wp:attachment":[{"href":"https:\/\/cvja.co.za\/journal\/wp-json\/wp\/v2\/media?parent=4973"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cvja.co.za\/journal\/wp-json\/wp\/v2\/categories?post=4973"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cvja.co.za\/journal\/wp-json\/wp\/v2\/tags?post=4973"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}